Pfizer is making headlines with its $7.3 billion acquisition of Metsera, a weight loss drugmaker, as it aims to capture a share of the booming obesity drug market. This deal highlights the growing demand for innovative obesity treatments and Pfizer's strategic pivot following setbacks in its own drug pipeline.
A team of scientists proposes a bold plan to combat Lyme disease on Nantucket by genetically engineering mice to be immune, raising both hope and ecological concerns in the community.
Texas-based Colossal Biosciences is making strides in their ambitious project to genetically engineer a version of the extinct dodo bird. With advances in cell culturing, experts are excited yet skeptical about the implications of such efforts on conservation.
David Baltimore, a renowned scientist and former president of Caltech, passed away at 87. His groundbreaking research and leadership transformed biology and higher education, leaving a lasting legacy.
Jim O'Neill, a Silicon Valley investor and advocate for unproven COVID treatments, is set to lead the CDC, sparking concerns over public health policies. His ties with Health Secretary Robert F. Kennedy Jr. may reshape America's health agenda.
Prepare for an exhilarating launch as NASA and SpaceX send 5,000 pounds of vital supplies and groundbreaking experiments to the International Space Station. Tune in for live coverage!
Discover how researchers at IBM and Moderna have leveraged quantum computing to predict the complex protein structure of mRNA, marking a significant advancement in vaccine technology.
Scientists have developed a groundbreaking 'disease-on-a-chip' model for ALS using stem cells, paving the way for potential new treatments. This innovative approach mimics early disease stages and could revolutionize ALS research.
In a stunning move, the FDA has put clinical trials for Sarepta's gene therapy on hold due to alarming safety concerns after multiple patient deaths linked to acute liver failure. The company faces scrutiny as it navigates the fallout.
Sarepta Therapeutics is under fire as another patient succumbs to acute liver failure linked to its gene therapy trial for muscular dystrophy, adding to the recent deaths of two teenage boys.
